Our cells naturally edit RNA. Korro’s OPERA® platform is designed to leverage this natural process by recruiting endogenous ADAR to make a precise A-to-I edit, potentially repairing a protein or creating one with enhanced functionality. Watch how it works: bit.ly/4chTNdW

What’s next for #RNAMedicines? Tomorrow at 9:15 a.m. ET, CEO @ramaiyar joins Chardan’s “RNA Medicines: Transcriptome Engineering” panel to discuss how our OPERA® platform could help shape the next decade of therapeutic innovation. #RNAEditing $KRRO

On Saturday, we joined @CureUCD’s 12th Annual #CureTheCycle ride to raise awareness and support the #UCD community. Thank you to all who rode and donated! This #CheckAmmoniaMonth, you can still help: charity.pledgeit.org/c/9t4pp… $KRRO

We’re heading to Denver for #OTS2026, Oct. 11–14! Our team will present posters P-027 and P-070 on new chemistries that expand the #RNAEditing capabilities of our OPERA® platform. Learn more: 2026oligomeeting.com/ $KRRO

We’ve dosed the first cohort in ANCHOR, our Phase 1/2 trial of KRRO-121, a subcutaneously delivered RNA-editing oligonucleotide (REO), for the potential treatment of #hyperammonemia in people with #UCDs or #hepaticencephalopathy. $KRRO #RNAEditing Learn more: bit.ly/4rOT4r6

@KorroBio CEO @Ramaiyar will join fireside chats at Citi on Sept. 9 and Cantor on Sept. 10 to discuss our approach to harnessing endogenous ADAR enzymes designed for precise, transient #RNAediting without permanently altering the genome. Learn: bit.ly/3TkAFWf $KRRO

At #SSIEM2026, Korro Bio’s Dafne Cardamone, Ph.D., will present preclinical data supporting the potential of KRRO-121, a GalNAc-conjugated #RNAediting oligonucleotide, as an approach for ammonia control in patients with #UCD agnostic of mutational background.

Today, we reported our Q2 2026 financial results and provided a corporate update, highlighting continued progress across our #RNAediting pipeline and corporate strategy. Learn more: bit.ly/4wHptRQ

Thank you to @CureUCD and everyone who connected with us at this year's conference. We're proud to share our research exploring #RNAediting as a potential approach for treating #hyperammonemia in people living with #ureacycledisorders and appreciate the opportunity to connect with patients, families, advocates, clinicians and researchers. We look forward to continuing our conversations!

We're looking forward to joining the #UreaCycleDisorder community at 2026 @NUCDF Family Conference. On Friday, Jonathan Fischer, Ph.D., will present a poster on our #RNAediting approach for the potential treatment of #hyperammonemia in patients with UCDs. bit.ly/452fWsn

At #EASL2026, we presented data from an electronic medical records analysis in hepatic encephalopathy highlighting the increased healthcare utilization associated with elevated ammonia. This ammonia burden represents a critical unmet need that we aim to address with KRRO-121. #HepaticEncephalopathy #Ammonia #RNAediting

We’ve selected KRRO-111 as a development candidate for the potential treatment of #AATD. In preclinical studies, KRRO-111 achieved >90% RNA editing of SERPINA1 transcripts, translating to ~90% repaired functional AAT protein. Learn more: ir.korrobio.com/news-release… $KRRO

Great to see KRRO-121 take the stage at #ASGCT2026! KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide for the potential treatment of hyperammonemia, the dangerous accumulation of ammonia in the blood. Excited to be advancing this program toward the clinic. #RNAediting #ASGCT

Thank you to everyone who joined our virtual Analyst Day and contributed to a thoughtful discussion. We appreciated the engagement and the opportunity to share insights on KRRO-121 for #hyperammonemia, alongside a powerful caregiver perspective. If you weren’t able to join live or would like to revisit the discussion, the full replay is now available here: event.webcasts.com/viewer/ev… $KRRO

ICYMI: Join us tomorrow for Korro Bio’s virtual Analyst Day, taking place at 8:00 AM ET. The program will include an overview of ammonia-driven diseases such as urea cycle disorders (UCD) and hepatic encephalopathy, a caregiver perspective on living with UCD, and updates on KRRO-121 for hyperammonemia. Live Q&A begins at 9:15 AM ET. Register and tune in: event.webcasts.com/starthere… $KRRO

Korro Bio will host a virtual Analyst Day on Tuesday, January 27, 2026, at 8:00 AM ET. The program will feature an overview of ammonia-driven diseases – urea cycle disorders (UCD) and hepatic encephalopathy, a caregiver’s perspective on living with UCD, and insights into KRRO-121, our development candidate for the potential treatment of patients with hyperammonemia. The Q&A session will take place at 9:15 AM. To learn more and join via webcast, visit: ir.korrobio.com/news-release… $KRRO

We were grateful for the opportunity to share Korro’s progress at #JPM2026 this week. Our CEO, @RamAiyar’s, presentation reflected the strength of our science, our disciplined decision-making, and the momentum across our pipeline. A few highlights we were excited to share: - KRRO-121, a GalNAc-conjugated ASO targeting hyperammonemia, has anticipated regulatory filing in H2’26, and an analyst teach-in planned for Jan 27. - GalNAc-conjugated ASO intended for AATD achieved >90% in vivo RNA editing — the highest reported to date; DC expected in H1’26. - GalNAc-conjugated ASO targeting AMPKγ1 for longevity showed improved liver health in early preclinical studies in mice. - ASO modulating TDP-43 intended for ALS reduced aggregation and mis-localization and restored normal splicing in preclinical studies. - KRRO-110, an LNP-encapsulated ASO for AATD, terminated Ph 1/2 clinical trial following a clear, data-driven decision. Watch a recording of the presentation here: ir.korrobio.com/events/event… $KRRO

Korro Bio will be attending the 44th Annual @JPMorgan Healthcare Conference in San Francisco. Our CEO, @ramaiyar will be presenting on Thursday, January 15, at 10:30 AM PT / 1:30 PM ET. Our COO Todd Chappell and CSO Loïc Vincent will also be participating at the conference. Learn more: ir.korrobio.com/news-release… $KRRO #JPM20256 #JPMHealthcare